Besprin

Aspirin 100 mg is a violet to bluish-violet enteric-coated tablet, biconvex and plain on both sides.
Aspirin is a salicylate NSAID and has many properties in common with non-aspirin NSAIDS. It has analgesic, anti-inflammatory and antipyretic properties; it acts as inhibitor of the enzyme cyclooxygenase, which results in the direct inhibition of the thromboxanes from arachidonic acid. Aspirin also inhibits platelet aggregation; non-acetylated salicylates do not.
Each enteric-coated tablet contains: Aspirin, USP 100 mg.

Pharmacology: Pharmacodynamics: Aspirin is a nonsteroidal anti-inflammatory agent with analgesic, antipyretic and anti-inflammatory properties which inhibits platelet aggregation by blocking thromboxane A2 synthesis. The thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to blood clotting and future risk of heart attack or stroke.
Pharmacokinetics: Aspirin and other salicylates are absorbed rapidly from the gastrointestinal tract but absorption following rectal administration is less reliable than after oral administration. Aspirin and other salicylates can also be absorbed through the skin.
Following oral administration, absorption of non-ionized aspirin occurs in the stomach and intestine. Some aspirin is hydrolysed to salicylate in the gut wall. After absorption, aspirin is rapidly converted to salicylate but during the first 20 minutes following oral administration, aspirin is the predominant form of the drug in the plasma.
Aspirin is 80% to 90% bound to plasma proteins and is widely distributed; its volume of distribution is reported to be 170 mL per kg body-weight in adults. As plasma drug concentration increases, the binding sites on the proteins become saturated and the volume of distribution increases. Both aspirin and salicylate have pharmacological activity although only aspirin has an anti-platelet effect. Salicylate is extensively bound to plasma proteins and is rapidly distributed to all body parts. Salicylates appears in breast milk and crosses the placenta.

Used in the initial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction, and for the prevention of cerebrovascular disorders such as stroke.

For the prevention of myocardial infarction and stroke, 75 mg to 100 mg daily, or as prescribed by the physician.

Aspirin overdose may occur when consumption is greater than 100 mg/kg/day which result in intoxication and potentially life-threatening. Symptoms of overdose may include dizziness, vertigo, tinnitus, sweating, nausea, vomiting, headache and confusion.
Treatment may include constant checking of vital functions, gastric lavage, repeated administration of activated charcoal, fluid and electrolyte management. Hemodialysis and peritoneal dialysis may also be performed.

Hypersensitivity to aspirin and other salicylates.
History of asthma.
Acute Gastrointestinal ulcer.
Severe renal failure.
Severe cardiac failure.

Aspirin should be cautiously administered, if at all, in patients prone to dyspepsia or known to have lesion of the gastric mucosa. It should not be administered to patients with haemophilia or other hemorrhagic disorders, or to treat patients with gout, since low doses increase urate concentrations or to those with an intolerance to aspirin (esp. aspirin sensitive asthmatics). Caution is necessary when renal or hepatic function is impaired. The use of aspirin in children under the age of 12 years is extremely limited because of the risk of Reye's syndrome. Mothers who are breastfeeding should not take aspirin.

Pregnancy: Aspirin should only be used by pregnant women when needed. During the first and second trimester of pregnancy, Aspirin intake should be low and duration of treatment should be as short as possible or should be avoided as possible. During the third trimester of pregnancy, Aspirin should be avoided since this may result in cardiopulmonary toxicity to the fetus.
Lactation: Aspirin passes into breastmilk in small quantities. Breastfeeding should be discontinued when Aspirin is use regularly or on intake of high doses.

The most common adverse effects occurring with therapeutic doses of aspirin are gastro-intestinal disturbances such as nausea, dyspepsia and vomiting. Aspirin may provoke various reactions including urticaria and other skin eruptions, angioedema, rhinitis and severe, even fatal paroxysmal bronchospasm and dyspnoea especially to those with asthma, chronic urticaria or chronic rhinitis. Aspirin increases bleeding time, decreases platelet adhesiveness and, in large doses, may cause hypoprothrombinaemia. Persons sensitive to aspirin may exhibit cross-sensitivity to other NSAIDs. Symptoms of salicylism include dizziness, tinnitus, deafness, sweating, nausea and vomiting, headache and mental confusion. In children, the use of aspirin has been implicated in some cases of Reye's syndrome.

Effects of aspirin on the gastrointestinal tract (GIT) are enhanced by alcohol. Aspirin may enhance the activity of coumarin anticoagulants, sulphonylurea, hypoglycemic agents, methotrexate, phenytoin and valproic acid. Aspirin diminishes the effects of uricosurics such as probenecid and sulphinpyrazone.

Store at temperatures not exceeding 30°C.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AC06 - acetylsalicylic acid ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.

Rx